What is CytomX Therapeutics Inc (CTMX) stock price today?

CytomX Therapeutics Inc (CTMX) currently trades at $4.05 per share. The stock has a market capitalization of $951.18M and a P/E ratio of —x.

Is CTMX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, CytomX Therapeutics Inc has a Smart Value Score of 26/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is CytomX Therapeutics Inc's revenue and earnings?

CytomX Therapeutics Inc has trailing twelve-month (TTM) revenue of $76.20M with profit margins of -22.80%. Earnings per share (EPS) is $-0.15.

Is CTMX stock overvalued or undervalued?

Based on our DCF model, CytomX Therapeutics Inc's intrinsic value is $14.23, representing a margin of safety of 60.93%. The stock currently trades at a P/E of —x.

CTMX

CytomX Therapeutics Inc

NASDAQ: CTMX · HEALTHCARE · BIOTECHNOLOGY

$4.05

-1.70% today

Updated 2026-04-29

Market cap

$951.18M

P/E ratio

—

P/S ratio

12.48x

EPS (TTM)

$-0.15

Dividend yield

—

52W range

$1 – $8

Volume

7.6M

Market cap

$951.18M

P/E ratio

—

P/S ratio

12.48x

EPS (TTM)

$-0.15

Dividend yield

—

52W range

$1 – $8

Volume

7.6M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.7

Growth

5.0

Quality

C+

2.0

Profitability

6.7

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$13.67

+237.53%

12-Month target

—

Intrinsic (DCF)

$14.23

Margin of safety

+60.93%

3 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ 60.93% below intrinsic value

Risks

- Thin margins at -22.80%

- Negative free cash flow $-23.44M

- Revenue declining -98.30% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$53.16M	$101.21M	$138.10M	$76.20M	$76.20M
Net income	$-97.30M	$-569000.00	$31.87M	$-17.37M	$-26.51M
EPS	—	—	—	—	$-0.15
Free cash flow	$-112.53M	$-56.88M	$-86.54M	$-75.81M	$-23.44M
Profit margin	-183.02%	-0.56%	23.08%	-22.79%	-22.80%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-17	OGDEN, CHRISTOPHER	Sale	19,323	$6.42
2026-03-17	MCCARTHY, SEAN A.	Sale	118,969	$6.42
2026-03-17	CHU, YU-WAYE	Sale	21,279	$6.42

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CTMX	$951.18M	26	6.7	2.0	6.7	5.0	+60.93%	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

CytomX Therapeutics Inc trades at $4.05. Our Smart Value Score of 26/100 indicates the stock is weak. TTM revenue stands at $76.20M. with profit margins at -22.80%. Our DCF model estimates intrinsic value at $14.23.

Frequently asked questions

What is CytomX Therapeutics Inc's stock price?

CytomX Therapeutics Inc (CTMX) trades at $4.05.

Is CytomX Therapeutics Inc overvalued?

Smart Value Score 26/100 (Grade F, Strong Sell). DCF value $14.23.

What is the price target of CytomX Therapeutics Inc (CTMX)?

The analyst target price is $13.67, representing +237.5% upside from the current price of $4.05.

What is the intrinsic value of CytomX Therapeutics Inc (CTMX)?

Based on our DCF model, intrinsic value is $14.23, a +60.9% margin of safety versus $4.05.

What is CytomX Therapeutics Inc's revenue?

TTM revenue is $76.20M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio12.48x

ROE-35.20%

Beta2.48

50D MA$4.86

200D MA$3.80

Shares out0.22B

Float0.15B

Short ratio—

Avg volume7.6M

Performance

1 week-7.42%

1 month-12.34%

3 months-28.22%

YTD-3.29%

1 year—

3 years—

5 years—

Compare

CTMX vs LLY →CTMX vs JNJ →CTMX vs ABBV →Stock screener →